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Abstract
Background: Oligodendroglioma (ODG) and oligoastrocytoma (OAC) are diffusely infiltrating
primary brain tumors whose pathogenesis remains unclear. We previously identified a group of
genes whose expression was inversely correlated with survival in a cohort of patients with
glioblastoma (GBM), and some of these genes are also reportedly expressed in ODG and OAC.
We examined the expression patterns and localization of these survival-associated genes in ODG
and OAC in order to analyze their possible roles in the oncogenesis of these two tumor types.
Methods: We used UniGene libraries derived from GBM and ODG specimens to examine the
expression levels of the transcripts for each of the 50 GBM survival-associated genes. We used
immunohistochemistry and cDNA microarrays to examine expression of selected survival-
associated genes and Id4, a gene believed to control the timing of oligodendrocyte development.
The expression of FABP7 and Id4 and the survival of patients with ODG and OAC were also
analyzed.
Results: Transcripts of most survival-associated genes as well as Id4 were present in both GBM
and ODG tumors, whereas protein expression of Id4 and one of the survival-associated genes,
brain-type fatty acid-binding protein (FABP7), was present in cells with astrocytic features, including
reactive and neoplastic astrocytes, but not in neoplastic oligodendrocytes. Id4 was co-expressed
with FABP7 in microgemistocytes in ODG and in neoplastic astrocytes in OAC. Id4 and FABP7
expression, however, did not correlate with the clinical outcome of patients with ODG or OAC
tumors.
Conclusion: Expression of Id4 and some of our previously identified GBM survival-associated
genes is present in developing or mature oligodendrocytes. However, protein expression of Id4
and FABP7 in GBM, ODG, and OAC suggests that this group of functionally important genes might
demonstrate two patterns of expression in these glioma subtypes: one group is universally
expressed in glioma cells, and the other group of genes is expressed primarily in neoplastic
astrocytes but not in neoplastic oligodendrocytes. Differential protein expression of these two
groups of genes in ODG and OAC may be related to the cellular origins and the histological
features of the neoplastic cells.
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Background
Gliomas are the most common subgroup of primary brain
tumors. The majority of gliomas are classified on the basis
of the histological appearance of the neoplastic cells:
astrocytoma (WHO grades I to IV), oligodendroglioma
(ODG; WHO grades II to III), and oligoastrocytoma
(OAC; WHO grades II to III). ODG consist of cells mor-
phologically resembling oligodendrocytes, and OAC con-
sist of a spectrum of neoplastic cells, some with
oligodendroglial features and others with astrocytic fea-
tures. ODG and OAC often recur at a higher pathological
grade, either as anaplastic ODG or OAC (grade III), or
astrocytoma grade IV (glioblastoma, GBM) [1]. The exact
genetic basis of the progression of lower-grade oligoden-
droglial tumors to higher-grade tumors is unclear. Both
ODG and OAC have significantly better prognosis than
GBM, with survival times ranging from 3 to 6 years, com-
pared to 1 year for GBM [1-3]. Several genetic alterations
in ODG and OAC, particularly the allelic loss of chromo-
some arms 1p and 19q, are used as prognostic indicators
to predict longer recurrence-free survival after radiation
therapy and/or chemotherapy [4-6].
In a previous study, we used gene expression profiling of
a panel of 29 GBM specimens to identify a group of 50
named genes, designated as survival-associated genes,
whose increased expression was inversely correlated with
patient survival [7]. The tumor specimens were derived
from 25 GBM tumors; in 4 of these specimens, 2 distinct
regions from each tumor were analyzed. A two-step algo-
rithm was used to identify the survival-associated genes
[7]. First, by analyzing patient survival in relation to gene
expression, a cluster of approximately 500 genes was iden-
tified whose increased expression in aggregate best
inversely correlates with patient survival. This cluster of
genes may represent a group of transcriptionally co-regu-
lated genes, so it is plausible that they are involved in
related biological processes. In the second step, we further
selected 50 genes within this cluster that showed signifi-
cantly greater variation in expression between different
tumors than between the paired samples from the 4 spec-
imens in which two distinct regions were analyzed. This
subset of 50 genes is more likely to encode intrinsic prop-
erties related to the behavior and prognosis of individual
GBM tumors. The prognostic value of one gene, brain-
type fatty acid-binding protein (FABP7), was validated
using two independent sets of GBM specimens [7].
The same microarray analyses also demonstrated that
there was increased expression of the 50 survival-associ-
ated genes in ODG and OAC tumors compared to normal
brain tissue [7]. This observation suggests that overexpres-
sion of the survival-associated genes may be common to
different glioma subtypes. Expression of other genes in
the group, such as Ptprz1 [8], Bcan [9], and Crmp5 [10], is
also detected in oligodendrocytes in developing or injured
brains, but their expression has not been reported in ODG
and OAC. Two genes in the group, Olig1 and Olig2, were
of particular interest since OLIG1 and OLIG2 are present
in neural progenitor cells and oligodendrocytes but not in
astrocytes and neurons. Olig1  and  Olig2  encode basic
helix-loop-helix (bHLH) transcription factors that play a
central role in oligodendrocyte development in the cen-
tral nervous system [11,12]. Olig1/Olig2-null mice show
complete failure of oligodendrocyte development, and
the precursor cells destined for an oligodendrocyte fate
differentiate instead into astrocytes [12]. An initial report
suggested that OLIG1 and OLIG2 might be markers for
identification of oligodendroglial tumors [13]. More
recent work, however, has demonstrated that OLIG1 and
OLIG2 are expressed in all glioma subtypes including
astrocytoma, ODG, and OAC [14,15].
In the group of 50 survival-associated genes, we did not
identify any gene that has been previously reported to be
a target of OLIG1 or OLIG2, or encode any protein known
to interact with OLIG1 and OLIG2. However, in the larger
cluster of 500 genes, Id4, a member of the helix-loop-helix
(HLH) transcription factor family, was present. Id pro-
teins dimerize with bHLH factors to prevent transcrip-
tional induction of downstream target genes, and regulate
a variety of functions in normal and neoplastic cells [16].
Several lines of evidence suggest the importance of Id4 in
oligodendrocyte development. Id4 is expressed in oli-
godendrocyte precursor cells and is thought to control the
timing of oligodendrocyte differentiation [17]. Enforced
expression of Id4 stimulates proliferation and blocks dif-
ferentiation of oligodendrocyte precursor cells [17]. Id4
was recently found to directly interact with OLIG1 and
OLIG2 in neural progenitor cells and to mediate the
inhibitory effects of bone morphogenetic protein-4 (BMP-
4) on oligodendroglial differentiation [18]. OLIG1/2 and
Id4 are co-expressed in neural progenitor cells, in which
OLIG1 and OLIG2 are localized in the nucleus whereas
Id4 is localized in the cytoplasm; when Id4 expression is
induced after BMP-4 treatment, OLIG1/2 localized pre-
dominantly to the cytoplasm and co-localizes with Id4
[18]. Despite this evidence in vitro, the expression of Id4
as it relates to OLIG1 and OLIG2 expression in ODG and
OAC has not been reported.
In this study, we analyzed in silico the levels of expression
for each survival-associated gene in the UniGene libraries
derived from GBM and ODG specimens. We then exam-
ined the expression of Id4 in tissue samples from ODG
and OAC using immunohistochemistry and found that,
in contrast to the patterns of expression for OLIG1 and
OLIG2, Id4 is preferentially expressed in cells of astrocytic
lineage in ODG and OAC tumors, which is similar to the
expression patterns of FABP7 (unpublished data). TheBMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
Page 3 of 12
(page number not for citation purposes)
differential expression of Id4 and FABP7 in cells of astro-
cytic phenotype in GBM and oligodendroglial tumors sug-
gests that specific transcription factors functioning in cell-
fate determination during development might also deter-




UniGene libraries for GBM and ODG were used to exam-
ine the normalized expression of the 50 survival-associ-
ated genes. Library derived from OAC was not available at
the time of analysis. UniGene assigns all human
Expressed Sequence Tag (EST) sequences that meet mini-
mal standards of quality to distinct "clusters". Each cluster
contains sequences that represent a unique human
expressed gene, and related information such as the tissue
types from which the libraries generating the sequences
were prepared [19]. The normalized expression for each
survival-associated genes as well as for Id4 in tissues was
recorded from the SOURCE database http://genome-
www5.stanford.edu/cgi-bin/source/sourceSearch. The
normalized expression of a gene represents the relative
expression level (in percentile) in different tissues and is
normalized for the number of EST clones from all libraries
reported by UniGene.
Tissue specimens
Paraffin-embedded and frozen specimens were obtained
from the Brain Tumor Research Center Tissue Bank at the
University of California, San Francisco after approval
from the Committee on Human Research.
Microarray analysis
Sample preparation and microarray methods followed
those of our previous study [7]. Briefly, total RNA was
extracted from frozen tissue specimens using Trizol (Invit-
rogen; Carlsbad, CA) followed by mRNA purification
using FastTrack (Invitrogen). Messenger RNA was reverse
transcribed to cDNA and directly labeled with Cy dyes
(Amersham Biosciences; Piscataway, NJ) before hybridi-
zation. Other detailed protocols can be found in web sup-
plement http://microarray-pubs.stanford.edu/gbm/.
Antibodies
FABP7 antiserum was a gift from Dr. Nathaniel Heintz
(Rockefeller University, New York, NY). A dilution of 1 to
400 was used for both immunostaining and migration
assays, and a dilution of 1 to 500 was used for immunob-
lotting. Dilutions of antibodies against glial fibrillary
acidic protein (GFAP) (ICN; Costa Mesa, CA) and Id4
(Santa Cruz Biotechnology, Santa Cruz, CA) for immuno-
histochemistry were 1:1000 and 1:100, respectively. A
dilution of 1 to 100 of the Id4 antibody was used for
immunoblotting. Peroxidase-conjugated and biotinylated
secondary antibodies were obtained from Vector Labora-
tories (Burlingame, CA).
Western blot analysis
The protein fraction of frozen tissue specimens was puri-
fied by isopropanol precipitation after removing total
RNA and genomic DNA using Trizol, washed several
times in 0.3 M guanidine hydrochloride in 95% ethanol,
and resuspended in 1% SDS. The protein concentration of
each sample was quantitated by using a Dc Protein Assay
Kit (Bio-Rad; Hercules, CA), and equal amounts of pro-
tein for each sample were separated by SDS-PAGE and
transferred to nitrocellulose membranes (Bio-Rad),
blocked with 10% skim milk, incubated with specific anti-
bodies, and visualized using a Super Signal West Pico
Chemiluminescent kit (Pierce; Rockford, IL).
Immunohistochemistry
All frozen tissue sections used for immunohistochemistry
were fixed in 4% formaldehyde, treated with H2O2,
blocked with normal serum, incubated with primary anti-
bodies at 4°C overnight or at room temperature (RT) for
2 hours, and incubated with biotinylated secondary anti-
body and peroxidase-labeled streptavidin at RT for 30
minutes. The DAB Reagent kit was used to visualize the
immunoreactivity (KPL; Gaithersburg, MA). Staining of
paraffin-embedded sections followed the same protocol,
except for prior de-waxing and antigen retrieval using
microwave heating.
Statistical analyses
All statistical analyses used SPSS for Windows (Release
11.5.0). Comparison of Id4 mRNA levels in gliomas was
analyzed using Student's t test. Correlation of Id4 and
FABP7 expression with patient survival was analyzed
using the Cox proportional hazards regression. A p value
≤ 0.05 was considered statistically significant for all tests.
Results
Transcripts of most survival-associated genes identified in 
glioblastomas are also detected in oligodendrogliomas
In our previous microarray analyses, we found elevated
expression of the GBM survival-associated genes in ODG
and OAC as compared to normal brain specimens [7].
However, expression of these 50 survival-associated genes
in ODG and OAC tumors has not been previously studied
except Olig1 and Olig2 [14]. To corroborate our previous
findings, we examined in silico the normalized expression
for each survival-associated gene as well as for Id4 in Uni-
Gene libraries derived from GBM and ODG tumors. We
found that, among the 50 genes, EST clones from 36 of the
genes (72%) were present in GBM libraries, and clones
from 30 of them (83%) were detected in libraries derived
from ODG specimens (Table 1). As expected, significant
numbers of EST clones representing Olig1, Olig2, and Id4BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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Table 1: Normalized expression of the survival-associated genes in GBM and oligodendrogliomas
Clone ID Gene Name GBM (%)1 Oligodendroglioma (%)
IMAGE:222457 ARC 56.16 3.53
IMAGE:383898 ARHN 5.1 28.36
IMAGE:1416420 ASCL1 5.79 7.39
IMAGE:32687 BCAN 12.5 38.22
IMAGE:290213 CACNG4 7.3 24.99
IMAGE:249688 CCND2 1.85 0.8
IMAGE:295116 CHRFAM7A ND2 ND
IMAGE:220096 CNGB1 ND ND
IMAGE:26295 CNR1 16.02 ND
IMAGE:248485 CRB1 ND 9.04
IMAGE:26505 CRMP5 14.59 5.42
IMAGE:41720 CRMP5 14.59 5.42
IMAGE:43771 CROC4 29.82 14.65
IMAGE:301104 CSPG5 8.02 16.41
IMAGE:33854 DBCCR1L ND 0.01
IMAGE:951022 DCX 19.01 3.78
IMAGE:361688 DPP6 2.18 14.1
IMAGE:81320 ETV1 1.76 4.17
IMAGE:279195 FABP7 ND 1.44
IMAGE:345626 FABP7 ND 1.44
IMAGE:773976 FABP7 ND 1.44
IMAGE:75759 FLJ10748 18.43 1.17
IMAGE:669379 GLCCI1 ND 0.44
IMAGE:49987 GRIA2 1.4 3.13
IMAGE:730016 KCNJ10 23.1 2.88
IMAGE:50939 KIAA0523 2.05 4.62
IMAGE:192543 KIAA0773 2.48 15.04
IMAGE:927112 KIAA0773 2.48 15.04
IMAGE:397495 LRRTM2 ND ND
IMAGE:787860 MGC45428 0.34 0.52
IMAGE:838478 NCALD 1.22 1.92
IMAGE:838668 NSE1 0.46 0.3
IMAGE:743187 NUDT10 ND ND
IMAGE:41214 OLIG1 2.92 33.23
IMAGE:26884 OLIG2 13.58 34.21
IMAGE:287468 PCDH17 ND 0.95
IMAGE:166934 PCDHGC3 9.46 8.46
IMAGE:753071 PHLDA1 4.27 3.71
IMAGE:866702 PTPN13 ND ND
IMAGE:30175 PTPRO ND 1.12
IMAGE:785148 PTPRZ1 5.34 8.2
IMAGE:161436 PTPRZ1 5.34 8.2
IMAGE:283976 PURG 13.16 ND
INAGE:1636226 SALL1 ND 20.31
IMAGE:207087 SCN 5.43 1.96
IMAGE:179534 SCNQ2 3.55 20.51
IMAGE:361659 SGEF 2.27 ND
IMAGE:357220 SHC3 ND ND
IMAGE:45877 SLC29A4 ND 1.44
IMAGE:38015 SLITRK2 ND ND
IMAGE:758266 THBS4 ND 1.19
IMAGE:34204 TRIM9 6.54 4.31BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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appeared in libraries from ODG. This result indicates that,
at least at the mRNA level, most of the survival-associated
genes identified in GBM can also be detected in ODG,
which correlates with the results from our previous micro-
array analyses.
Id4 protein is readily detected in glioblastomas and 
oligoastrocytomas but not in oligodendrogliomas
Because the in silico analysis of tumor specimens cannot
distinguish the cellular source of expression, we used
immunohistochemistry to localize the expression of Id4
in GBM and oligodendroglial tumors. The specificity of
Id4 antibodies was demonstrated by detection of a 15 kD
band on immunoblot using Trizol extracts of GBM and
normal brain specimens (Figure 1A). Id4
immunoreactivity was found in 10% to 100% of tumor
cells in 12 of the 13 GBM specimens we examined (92%),
and Id4 in both nucleus and cytoplasm could be detected
in immunoreactive cells (Figure 1B). Among the 21 ODG
tumors examined, expression of Id4 was seen in some
reactive astrocytes but was essentially negative in neoplas-
tic oligodendrocytes (Figure 1C), while unequivocal Id4
staining was observed in some neurons associated with
tumor cells (data not shown). We also examined 10 OAC
specimens, all of which had GFAP-positive neoplastic
cells and 5 of them (50%) had detectable Id4 immunore-
activity in GFAP-positive areas (Figure 1D).
Our in silico and immunohistochemistry data showed that
Id4 mRNA had comparable levels in UniGene libraries
derived from GBM and ODG specimens (Table 1), while
Id4 protein was detected only in neoplastic astrocytes but
not in neoplastic oligodendrocytes (Figure 1). To confirm
the discrepancy of the Id4 expression between mRNA and
protein levels in ODG tumors, we examined expression of
Id4 mRNA in selected GBM (N = 7), ODG (N = 3), and
OAC specimens (N = 3) from a previous microarray study
[7]; all these tumor specimens had been examined for Id4
expression with immunohistochemistry and showed Id4
immunoreactivity in neoplastic astrocytes but not in
IMAGE:951705 ZCCHC6 0.76 ND
IMAGE:359684 ZDHHC22 32.39 17.7
Id4 2.1 8.29
1 Normalized expression level of each gene is defined as the number of EST clones detected in tumor libraries (GBM or oligodendrogliomas) 
divided by the number of clones detected in all libraries reported by UniGene.
2 ND, not detected.
Table 1: Normalized expression of the survival-associated genes in GBM and oligodendrogliomas (Continued)
Id4 is preferentially expressed in cells of astrocytic lineage Figure 1
Id4 is preferentially expressed in cells of astrocytic lineage. 
The specificity of anti-Id4 antibodies was confirmed with 
immunoblotting by using Trizol extracts of a GBM specimen 
and white matter (WM) from a normal subject (A). Cytoplas-
mic Id4 immunoreactivity was prominent in most GBM 
examined (B). In oligodendrogliomas, neoplastic oligodendro-
cytes were essentially negative for Id4, whereas some reac-
tive astrocytes could be found Id4-positive (C). Id4 
immunoreactivity could also be seen in the astrocytic com-
ponent of some oligoastrocytomas (D). Bar in B, 50 µm.BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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neoplastic oligodendrocytes. Unlike protein expression,
we found that Id4 mRNA had similar levels in specimens
derived from all three tumor types examined in this anal-
ysis (p = 0.6, Figure 2).
Id4 and FABP7 are co-expressed in microgemistocytes of 
oligodendrogliomas and in neoplastic astrocytes of 
oligoastrocytomas
Although Id4 has an expression pattern similar to OLIG1
and OLIG2 in GBM, Id4 protein was preferentially
detected in reactive and neoplastic astrocytes but not in
neoplastic oligodendrocytes. We then examined whether
this difference occurred with other genes in the survival-
associated group. We chose to study expression of FABP7
in ODG and OAC and found that, similar to Id4, FABP7
was expressed in OAC but not in the neoplastic oli-
godendrocytes (unpublished data). We therefore exam-
ined whether both genes are co-expressed in ODG and
OAC tumors.
Microgemistocytes are a small subset of neoplastic cells
that may be seen in ODG tumors, but the exact cellular
origin of this type of cells is still controversial. Six ODG
specimens had an easily discernible group of GFAP-posi-
tive microgemistocytes (Figure 3A and 3B), and in 4 of
these specimens both FABP7 and Id4 immunoreactivity
was present in the cytoplasm (Figure 3C and 3D). No Id4
immunoreactivity was detected in FABP7-negative micro-
gemistocytes (Figure 3E to 3H). Among the 10 OAC spec-
imens examined, 8 were positive for FABP7, and 5 of these
8 specimens had detectable Id4 immunoreactivity. In this
subgroup of 5 OAC specimens (Figure 4A), GFAP (Figure
4B), FABP7 (Figure 4C), and Id4 (Figure 4D) were
observed in the same population of neoplastic astrocytes.
Microarray analysis of Id4 mRNA in glioma tissues that have been examined with immunohistochemistry Figure 2
Microarray analysis of Id4 mRNA in glioma tissues that have been examined with immunohistochemistry. The expression levels 
of Id4 were represented by the log 2-transformed ratio of the fluorescence signal in tumor to the signal in hybridization refer-
ence. Two IMAGE clones (788234 and 789369) corresponding to different regions of the Id4 gene with interpretable data were 
selected for analysis. All three tumor types examined in this analysis demonstrated similar levels of Id4 mRNA (p values 
between 0.33 and 0.75).BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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FABP7 and Id4 are co-expressed in microgemistocytes in oligodendrogliomas Figure 3
FABP7 and Id4 are co-expressed in microgemistocytes in oligodendrogliomas. H & E staining showed typical morphology of 
microgemistocytes with eosinophilic cytoplasm (A) with strong GFAP immunoreactivity (B). In consecutive sections, cytoplas-
mic FABP7 (C) and Id4 (D) staining was detected in the same group of cells. However, microgemistocytes are negative for both 
FABP7 and Id4 in some oligodendrogliomas. H & E (E) and GFAP (F) staining showed the presence of microgemistocytes that 
were essentially negative for FABP7 (G) and Id4 (H). Some FABP7-positive cells were reactive astrocytes (G). Bar in A, 50 µm.BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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Expression of Id4 and FABP7 in relation to the clinical 
outcome of patients with oligodendrogliomas and 
oligoastrocytomas
Given the findings that nuclear FABP7 immunoreactivity
predicts the outcome of patients with GBM, and that Id4
and FABP7 are co-expressed in OAC and in microgemisto-
cytes of ODG, we tested whether expression of Id4 and
FABP7 might have prognostic value for patients with
ODG or OAC. Among the tumor specimens on which we
performed immunohistochemistry, we analyzed 15 ODG
(grade III) and 10 OAC (1 grade II and 9 grade III) for
which we could obtain clinical information about the
patients (Table 2). The median age for this group of
patients with ODG and OAC was 51 and 45 years old,
respectively. The follow-up period from the time of initial
diagnosis ranged from 3 to 9 years. Although they were
not treated under the same protocol, all had surgical resec-
tions and received both radiotherapy and alkylating
chemotherapy.
Two of the 15 patients with ODG have died, and their
tumors were negative for Id4/FABP7 immunoreactivity
(Table 2). Two of the 10 patients with OAC have died; one
tumor had no detectable Id4 and FABP7 immunoreactiv-
ity, while the other one showed a similar degree of cyto-
plasmic/nuclear FABP7 and cytoplasmic Id4 staining to
the other 4 specimens derived from patients who were still
alive (Table 2). There were no characteristics that distin-
guished the living subjects from those diseased. We used
Cox regression to analyze the correlation of Id4 and
FABP7 immunoreactivity with patient survival by the
presence of immunoreactive microgemistocytes (for strat-
ifying ODG patients), or by the immunoreactivity in
nucleus alone or in both nucleus and cytoplasm (for strat-
ifying OAC patients). Our limited data showed that
expression of Id4 and FABP7 did not correlate with the
survival of patients with ODG or OAC tumors (Table 3).
Discussion
Oligodendroglial tumors are the third most common type
of primary brain tumor. They have a diffusely infiltrative
growth pattern similar to astrocytic tumors but tend to
have a better prognosis. The exact genetic basis for the
development of gliomas with astrocytic, oligodendroglial,
or mixed (oligoastrocytic) phenotypes is unknown.
However, it has been recognized that specific genetic
backgrounds do affect the clinical outcome of patients
with oligodendroglial tumors. A subgroup of oligoden-
droglial tumors with allelic loss of chromosome arms 1p
and 19q respond better to treatment [20]. Several genetic
aberrations frequently detected in GBM, such as muta-
tions in the p53 gene, Egfr overexpression or amplifica-
tion, and deletion of the p16/Cdkn2A  gene, are also
associated with poor prognosis in both ODG and OAC.
Defining the genetic features of these glial neoplasms has
both diagnostic and potentially therapeutic benefits. Pre-
viously, we identified a group of genes that stratifies
patients with histologically identical GBM into two
groups with markedly different survival [7]. The expres-
sion of FABP7, in particular, demonstrated a strong
inverse correlation with patient survival, and may be
involved in the pathogenesis of GBM (unpublished data).
Our data suggested that this group of genes that includes
Olig1 and Olig2 might be also expressed in ODG and OAC
[7]. Therefore, we hypothesized that our group of survival-
associated genes originally identified in GBM might also
be associated with the pathobiology of oligodendroglial
neoplasms.
We examined in silico the expression of the transcripts for
each survival-associated gene in UniGene libraries derived
from GBM and ODG tumors, and most could be identi-
fied in both tumor types. The transcripts of the Fabp7 gene
were not detected in the GBM libraries from UniGene
(Table 1). This might be because FABP7 immunoreactivity
FABP7 and Id4 are co-expressed in astrocytic component of  oligoastrocytomas Figure 4
FABP7 and Id4 are co-expressed in astrocytic component of 
oligoastrocytomas. H & E staining demonstrated the pres-
ence of neoplastic astrocytes with eosinophilic cytoplasm and 
elongated nuclei (A) that were also GFAP-positive (B). The 
same population of cells was positive for both FABP7 (C) and 
Id4 (D) in consecutive sections of the frozen specimen. The 
scale of the photomicrographs is the same as in Figure 1B.BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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was observed in only half to two-thirds of the GBM speci-
mens as shown in our previous studies [7], and the
number of libraries reported by UniGene may not be suf-
ficient to "capture" all potentially positive tumors.
Another limitation of this type of analysis is that the cel-
lular source for positive gene expression cannot be deter-
Table 2: Summary of clinical data of patients with ODG and OAC, and immunohistochemistry of their tumors.
Tumor ID Diagnosis Alive/Dead4 Survival Time 
(year)5
GFAP FABP7 Id4
2650 ODG III1 A 9.12 - (MG+)6 - (MG+) - (MG+)
2963 ODG III A 7.28 - (MG+) - (MG+) - (MG+)
3081 ODG III A 6.97 - (MG+) - (MG+) - (MG+)
3474* ODG III A 5.67 + (?)7 --
3492 ODG III D 5.29 - - -
3551* ODG III A 5.42 NI8 --
3607 ODG III D 3.91 - - -
3651* ODG III A 5.09 - - -
3767 ODG III A 4.73 - - -
3768 ODG III A 4.73 - - -
3815 ODG III A 4.59 - (MG+) -/+9 (MG-) - (MG-)
4115 ODG III A 3.64 - (MG+) - (MG+) - (MG+)
4142 ODG III A 3.55 - (MG+) - (MG-) - (MG-)
4167 ODG III A 3.48 -/+ -/+ -
4253 ODG III A 3.26 - - -
2450 OAC III2 A 9.9 + + (cyto/nuc)10 + (cyto)
2459 OAC III A 9.9 + + (cyto/nuc) + (cyto)
2533* OAC III A 6.55 + + (cyto) -
2609* OAC III A 9.27 + + (cyto/nuc) -
2622* OAC III D 5.75 + - -
2668 OAC III D 8.97 + + (cyto/nuc) + (cyto)
3304 OAC III A 6.27 + + (cyto) + (cyto)
3378 OAC III A 5.97 + + (cyto/nuc) + (cyto/nuc)
3729 OAC II3 A 4.85 + + (cyto) -
4141 OAC III A 3.55 + - -
1 ODG III, oligodendroglioma, grade III.
2 OAC III, oligoastrocytoma, grade III.
3 OAC II, oligoastrocytoma, grade II.
4 Alive or dead of the patients was determined by the date of the most recent follow-up (9/30/04).
5 The date of diagnosis to 9/30/04 was defined as the survival time for patients who were alive.
6 Positive in microgemistocytes (MG).
7 This was a frozen section with 50% of tumor cells positive for GFAP, but H & E did not show microgemistocytes; the result was therefore 
questionable.
8 This was a frozen section with lots of freezing artifect; the result was not interpretable.
9 A small group (<5%) of tumor nuclei were positive.
10 Both cytoplasm and nuclei were positive.
* Specimens that have been analyzed by cDNA microarrays.
Table 3: Cox regression analyses of FABP7 and Id4 immunoreactivity in relation to the survival of ODG and OAC patients
Tumor Markers Immunoreactivity Status no. of cases p
ODG FABP7 & Id4 MG+ vs. MG- 4 vs. 11 0.524
FABP7 cyto/nuc+ or cyt+ vs. - 8 vs. 2 0.859
OAC nuc+ vs. nuc- 5 vs. 5 0.581
Id4 cyto/nuc+ or cyt+ vs. - 5 vs. 5 0.573BMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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mined. For this reason, we validated our analysis by
examining specific genes at the tissue level using
immunohistochemistry.
Our data demonstrate that Id4 and FABP7 proteins are
primarily localized in cells with astrocytic features but not
in neoplastic oligodendrocytes. Therefore, the expression
of survival-associated genes in ODG and OAC can be
divided into at least two subgroups; genes such as Olig1
and Olig2 that are expressed in all glial tumors, and genes
such as Fabp7 that are restricted to astrocytes. This division
is supported by our immunohistochemical analysis of
another survival-associated gene, Ptprz1, which has an
expression pattern in ODG and OAC similar to Id4 and
FABP7 (unpublished data).
Examining the biological roles of OLIG1, OLIG2, and Id4
in developing central nervous system provides a plausible
explanation for these varying patterns of gene expression.
OLIG1 and OLIG2 play a central role in oligodendrocyte
development, as illustrated by their expression in fully dif-
ferentiated oligodendrocytes [21], the failure of oli-
godendrocyte differentiation in Olig1/Olig2-knockout
mice [12], and the expansion of oligodendroglial cells in
vivo  following overexpression of OLIG1 and OLIG2
[22,23]. Oligodendrocyte development exemplifies the
principle of 'switching' of cell fate by alteration of tran-
scription-factor expression levels. For example, overex-
pression of BMP-4 in mice results in a significant decrease
in the number of oligodendrocytes, accompanied by an
increase in astrocytes [24], coincident with the gradual
decline of OLIG1 and OLIG2 [18]. Ectopic expression of
Id4 in neural progenitor cells recapitulates the effect of
BMP-4 by blocking oligodendrocyte maturation, stimulat-
ing cell-cycle progression of oligodendrocyte precursor
cells, and promoting astrocyte formation [17,18]. Id4
expression decreases when the precursor cells are induced
to differentiate into oligodendrocytes [17]. OLIG1,
OLIG2, and Id4 are co-expressed in neural progenitor cells
but in different subcellular compartments (OLIG1 and
OLIG2 are localized in the nucleus and Id4 is localized in
the cytoplasm). BMP-4 treatment induces Id4 expression
along with translocation of OLIG1 and OLIG2 to the cyto-
plasm; therefore, it was proposed that cytoplasmic Id4
must reach a critical level to effectively sequester OLIG1
and OLIG2 to prevent their nuclear translocation, and
subsequent specification of the cell fate [18].
Both astrocytomas and oligodendroglial tumors in
humans demonstrate diffuse expression of OLIG1 and
OLIG2, although expression of OLIG2 is lower and
increasingly variable and heterogeneous in GBM as com-
pared to ODG tumors [14]. Conversely, Id4 is negative in
neoplastic oligodendrocytes, positive in neoplastic
astrocytes in half of the OAC specimens examined, and
positive in almost all GBM specimens. This pattern of Id4
expression parallels its expression in neural progenitor
cells during their commitment to either an oligodendro-
cytic or astrocytic lineage. Based on these observations,
one possibility is that astrocytomas and oligodendroglial
tumors may arise from a common cell type with features
similar to the OLIG1/2-positive neural progenitor cells.
Increased expression of Id4 by growth-factor stimulation
or genetic mutation may switch transformed cells towards
an astrocytic phenotype, whereas failure of Id4 expression
would give rise to pure ODG.
The astrocytic component of OAC may represent a focal
area of Id4 expression in tumor subpopulations occurring
at later stages after tumor initiation, leading to the co-
expression of Id4 with OLIG1 and OLIG2 in neoplastic
astrocytes and lack of Id4 expression in neoplastic oli-
godendrocytes. This potential mechanism for the
presence of mixed cell populations in OAC is consistent
with genetic analyses demonstrating that astrocytic and
oligodendroglial components within an oligoastrocy-
toma might be of monoclonal origin [25]. Furthermore,
the magnitude and the timing of Id4 induction could
explain the heterogeneity of OAC, in that one group is
genetically related to ODG, and the other one related to
astrocytomas [26,27]. However, the astrocytic component
in OAC may have a different transitional nature from the
GFAP/Id4/FABP7-positive cell types in ODG, since a
recent study found that no OLIG1 expression is seen in
GFAP-positive microgemistocytes in ODG tumors [28]. In
this study, we did not find a correlation between Id4 and
FABP7 expression and the clinical outcome of patients
with OAC, but it may be of interest to repeat the analyses
in a larger cohort of astrocytoma-like OAC as defined in
the study by Maintz and others [26,27].
In conclusion, we show that Id4 expression is present pri-
marily in neoplastic astrocytes in both oligodendroglial
tumors and GBM, which is in contrast to the expression
patterns of Olig1 and Olig2, two survival-associated genes
originally identified in GBM tumors. Two other survival-
associated genes, Fabp7 and Ptprz1, show expression pat-
terns similar to Id4. Based on the function of Id4, OLIG1,
and OLIG2 during normal development, our data suggest
that Id4 and potentially other genes such as Fabp7 and
Ptprz1 might account for the formation of distinct glioma
subtypes during oncogenic progression.
Conclusion
Id4 expression is present primarily in neoplastic astrocytes
in both oligodendroglial tumors and GBM, which is in
contrast to the expression patterns of OLIG1 and OLIG2,
two survival-associated genes originally identified in GBM
tumors. FABP7 show expression patterns similar to Id4,
indicating that the survival-associated genes can beBMC Clinical Pathology 2005, 5:6 http://www.biomedcentral.com/1472-6890/5/6
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divided into at least two groups in ODG and OAC. The
functions of Id4, OLIG1, and OLIG2 during normal devel-
opment, and our data suggest that Id4 and potentially
other proteins such as FABP7 and PTPRZ1 might account
for the formation of distinct glioma subtypes during
oncogenic progression.
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